Drug Trial Radar · NCT07335497
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Feb 17, 2026
Primary completion
Feb 2029
Study completion Feb 2029
Sponsor
- Lead sponsor
- Crescent Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Conditions
- Locally Advanced / Metastatic Solid Tumors
Interventions
CR-001Drug
Intravenous Infusion
PaclitaxelDrug
Intravenous Infusion
trifluridine and tipiracilDrug
Oral
PemetrexedDrug
Intravenous Infusion
CarboplatinDrug
Intravenous Infusion
OxaliplatinDrug
Intravenous Infusion
GemcitabinDrug
Intravenous Infusion
CisplatinDrug
Intravenous Infusion
CapecitabineDrug
Oral
FOLFOXDrug
Intravenous Infusion + Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Dose Escalation) - Incidence and nature of dose-limiting toxicitiesTime frame: From the first dose of study drug up until approximately 1 month
- Part 1 (Dose Escalation) - Characterization of the maximum tolerated dose, if applicableTime frame: From the first dose of study drug up until approximately 1 month
- All parts - Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment - emergent serious adverse eventsTime frame: From the first dose of study drug until 90 days after the last dose of study drug
- All parts - Incidence and severity of TEAEs leading to dose modificationsTime frame: From the first dose of study drug until 90 days after the last dose of study drug
- All parts - Incidence and severity of TEAEs leading to treatment discontinuationTime frame: From the first dose of study drug until 90 days after the last dose of study drug
- Part 3 (Dose Expansion) - Overall response rate (ORR) by Investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Time frame: From the first dose of study drug until 90 days after the last dose of study drug
Locations
36 sites in 10 countries. Site status is shown where the registry gives one.
Clinical Study Site
Birmingham, Alabama · Recruiting
Clinical Study Site
Los Angeles, California · Recruiting
Clinical Study Site
Denver, Colorado · Recruiting
Clinical Study Site
Washington D.C., District of Columbia · Recruiting
Clinical Study Site
Orlando, Florida · Recruiting
Clinical Study Site
Sarasota, Florida · Recruiting
Clinical Study Site
Detroit, Michigan · Recruiting
Clinical Study Site
Grand Rapids, Michigan · Recruiting
Clinical Study Site
New York, New York · Recruiting
Clinical Study Site
Columbus, Ohio · Recruiting
Clinical Study Site
Pittsburgh, Pennsylvania · Recruiting
Clinical Study Site
Nashville, Tennessee · Recruiting
Clinical Study Site
Dallas, Texas · Recruiting
Clinical Study Site
San Antonio, Texas · Recruiting
Clinical Study Site
West Valley City, Utah · Recruiting
Clinical Study Site
South Brisbane, Queensland, Australia · Withdrawn
Clinical Study Site
Villejuif, France · Recruiting
Clinical Study Site
Dublin, Ireland, Ireland · Recruiting
Clinical Study Site
Florence, Italy · Recruiting
Clinical Study Site
Milan, Milano, Italy · Recruiting
Clinical Study Site
Candiolo, Torino, Italy · Recruiting
Clinical Study Site
Bucharest, Romania · Recruiting
Clinical Study Site
Cluj-Napoca, Cluj, Romania · Recruiting
Clinical Study Site
Seongnam-si, South Korea · Recruiting
Clinical Study Site
Seoul, Seoul, South Korea · Recruiting
Clinical Study Site
Seoul, Seoul, South Korea · Recruiting
Clinical Study Site
Seoul, Seoul, South Korea · Recruiting
Clinical Study Site
Songpa-dong, Seoul, South Korea · Recruiting
Clinical Study Site
Barcelona, Barcelona, Spain · Recruiting
Clinical Study Site
Logroño, La Rioja, Spain · Recruiting
Clinical Study Site
Madrid, Madrid, Spain · Recruiting
Clinical Study Site
Madrid, Madrid, Spain · Recruiting
Clinical Study Site
Kyiv, Ukraine · Recruiting
Clinical Study Site
Hampstead, United Kingdom · Recruiting
Clinical Study Site
London, United Kingdom · Recruiting
Clinical Study Site
Manchester, Greater Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.